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Chronic Rejection after Lung Transplantation
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A new classification system for chronic rejection in lung transplantation was recently proposed. Chronic lung allograft dysfunction 
(CLAD) is regarded as chronic rejection after excluding other causes of allograft dysfunction. CLAD is divided into obstructive 
CLAD (bronchiolitis obliterans syndrome) and restrictive CLAD (restrictive allograft syndrome). In this review, we will review 
the latest concepts and current controversies regarding the new CLAD terminology, diagnostic approach, risk factors and possible 
treatment options.
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INTRODUCTION
The number of lung transplantation (LTx) is recently in-
creasing, however, the rate of long-term survival after LTx 
remains low. According to the recent report of International 
Society for Heart and Lung Transplantation (ISHLT), 5-year 
survival is only about 55%(1). Chronic rejection is one of 
the major problem hindering long-term survival in patients 
with LTx and more than 50% patients at 5-year posttrans-
plant develop chronic rejection(1).
Originally, pathological obliterative bronchiolitis (OB) was 
regarded as chronic rejection(2,3). However, it is difficult 
to prove on small biopsies. As a result, the term bronchiolitis 
obliterans syndrome (BOS) was adopted to explain syn-
drome of late-onset and chronic decline of allograft func-
tion (＞20% decline in forced expiratory volume in 1s, 
FEV1, compared to the best postoperative baseline). BOS or 
OB was considered the equivalent to chronic rejection(4). 
However, some LTx patients may develop a restrictive pat-
tern of allograft dysfunction which is different from BOS(5,6). 
This syndrome was defined as restrictive allograft syndrome 
(RAS)(6,7). In this review, we will review about chronic 
rejection based on these new insights and paradigm shifts.
1. Chronic lung allograft dysfunction (CLAD)
Recently, a new classification system for chronic rejection 
was proposed(8). CLAD is regarded as chronic rejection af-
ter excluding other causes of allograft dysfunction. CLAD 
is defined as a persistent (for at least 3 weeks) decline of 
FEV1 and/or forced vital capacity (FVC) of at least 20% 
in comparison with the baseline, which is considered as the 
mean value of the two best posttransplant measurements 
with at least 3 weeks interval(8).
CLAD is not the term of diagnosis but the status of per-
sistent decline compared to the best posttransplant lung 
function values. Therefore, every possible causes of persis-
tent decreased function should be ruled out. When other 
specific causes are excluded (Table 1), the graft dysfunction 
can be explained by CLAD.
After excluding other causes leading to the decline of al-
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Table 2. Original and proposed classification of BOS 
Original classification Current proposition
BOS 0 FEV1 80% or more of baseline BOS 0 FEV1＞90% of baseline and FEF25∼75% of baseline
BOS 0-p FEV1 81% to 90% of baseline and/or FEF25∼75% ＜75% of baseline
BOS 1 FEV1 66% to 80% of baseline BOS 1 FEV1 66% to 80% of baseline
BOS 2 FEV1 51% to 65% of baseline BOS 2 FEV1 51% to 65% of baseline
BOS 3 FEV1 50% or less of baseline BOS 3 FEV1 50% or less of baseline
Abbreviations: BOS, bronchiolitis obliterans syndrome; FEF25∼75%, mild-expiratory flow rate; FEV1, forced expiratory volume in 1 second.
Adapted from Table 1 of reference [10].
Table 1. Confounding factors leading to FEV1 decline other than
chronic rejection
Allograft-related
  Persistent acute rejection
  ARAD
  Infection/Colonization
  Anastomotic stricture
  Disease recurrence
  Follicular bronchiolitis
Extra-allograft
  Pleural disease
  Diaphragm dysfunction
  Native lung hyperinflation
  Other causes
Abbreviations: ARAD, azithromycin-responsive allograft dysfunction.
Adapted from Fig. 1 of reference [8].
Table 3. Risk factors for BOS
Primary graft dysfunction
Acute cellular rejection
Lymphocytic bronchiolitis
Antibody-mediated rejection (de novo donor-specific anti-human 
leukocyte antigen antibodies)
Gastroesophageal reflux and microaspiration
Introduction/Colonization
Persistent neutrophil reflux and sequestration
Autoimmunity (e.g. collagen V sensitization)
Air pollution
Genetic factors
Abbreviations: BOS, bronchiolitis obliterans syndrome.
Adapted from Table 1 of reference [11].
lograft function, further work-up is needed. Work-up gen-
erally include thorax computed tomography (CT) with both 
insipiratory and expiratory phase, full pulmonary function 
test (PFT), and bronchoscopy with transbronchial biopsies 
(TBLB), bronchoalveolar lavage (BAL) with cultures and 
total and differential cell count. The phenotype of CLAD 
can be classified based on the results of work-up.
1) Bronchiolitis obliterans syndrome (BOS)
OB has been the hallmark of chronic rejection since 1984, 
at which Burke et al. describe that term(2). OB is a fi-
broproliferative obliteration in the small airway and it is 
difficult to prove by TBLB due to low sensitivity(2,3,9). As 
a result, expert group in ISHLT suggested concept of BOS 
as the clinical term correlated with OB(4). The definition 
of BOS was a persistent, progressive and irreversible decline 
of FEV1 with airway obstructive pattern and the category 
was divided to 4 groups based on FEV1 decline in compar-
ison with the baseline, which is considered as the mean val-
ue of the two best posttransplant measurements with at least 
3 weeks interval(4). At first update about BOS definition, 
one more category was added, that was BOS 0-p (potential 
BOS), which further included values of forced expiratory 
flow at 25 and 75% of vital capacity (FEF25∼75%). And defi-
nition of staging system proposed in this statement was 
shown in Table 2(10). Second revision about BOS approved 
by ISHLT was recently published. It updated the patho-
physiology of BOS and strategies to manage patients with 
BOS(11).
Various risk factors for BOS has been suggested(11, 
Table 3) Among them, the role of antibody-mediated re-
jection with the development of donor-specific antibodies 
(DSA) has been identified recently. Recipients with early 
or late development of DSA and persistent DSA tend to 
easily develop to BOS(12-14). And the role of non-HLA 
antibodies to self- antigens (collagen V and K-1 tubulin) 
has been suggested(15).
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The treatment of BOS is still difficult due to the unclarity 
of pathophysiology and causes. However, several treatment 
has been tried although most modalities have shown minimal 
success rate. It was switching immunosuppressive agents, ad-
dition of montelukast, cyclophosphamide, methotrexate, to-
tal lymphoid irradiation and extracorporeal photophe-
resis(16). Recently, fundoplication can be performed when 
gastroesophageal reflux is diagnosed in BOS patients(11). 
Additionally, azithromycin can be potentially beneficial in 
BOS, and there are many reports about that. There is report 
that about 40% of BOS patients can respond to azithro-
mycin(17). BAL neutrophilia (＞15%) was suggested as 
predictive marker of responsiveness to azithromycin, how-
ever this is controversial due to neutrophilia can be shown 
due to coexistent infection(18-22). Responders to azi-
thromycin which is defined as a FEV1 increase of ≥10% 
after a 2∼3 month treatment were initially categorized as 
neutrophil-reversible allograft dysfunction (NRAD), but re-
naming as azithromycin – responsive allograft dysfunction 
(ARAD) was recently suggested(11,23). Considering the 
definition of CLAD, ARAD may be a potential confounder 
of BOS. Therefore, it is advised to take azithromycin for 
about 3 months in all patients with decline of lung function 
consistent with CLAD/BOS(8,11). Finally, retransplantation 
can be performed in well selected patients for only curative 
purpose of BOS(11,24).
2) Restrictive CLAD (rCLAD): restrictive allograft 
syndrome (RAS)
Recently, several groups reported about the existence of 
a restrictive phenotype of CLAD (rCLAD). There is no in-
ternational and consistent definition for rCLAD, however, 
several groups suggested the different diagnostic criteria. 
Woodrow et al. divided CLAD patients to restrictive CLAD 
(FVC decline ≥20%) with pleuroparenchymal infiltrates on 
CT and obstructive CLAD (FVC decline ＜20%)(25). Sato 
et al. suggested the concept of RAS which is a group of 
patients with restrictive PFT decline (a decline in TLC of 
≥10% compared to the best posttransplant baseline and 
with a decline in FEV1 ≥20%)(6). This definition has sev-
eral problems including not applying to single lung trans-
plant and not performing TLC routinely. Other group used 
the ratio of FEV1/FVC ratio in defining rCLAD, and this 
definition has problem of normal or increased FEV1/FVC 
if FVC and FEV1 simultaneously is decreased(26). Todd et 
al conducted a study using spirometry alone to diagnose 
rCLAD(27). They divided CLAD as restrictive (FVC/FVCbest 
＜0.80) and obstructive (FVC/FVCbest ≥0.80) CLAD.
CT scan can be useful for diagnosing rCLAD. CT scan 
in rCLAD showed persistent infiltration, volume loss and hi-
lus retraction to pleuroparenchymal fibro-elastosis(7). Biopsy 
findings also can help to diagnose patients with rCLAD. One 
recent study showed that acute fibrinoid-organizing pneu-
monia (AFOP) was diagnosed on TBLB biopsies with FEV1 
decrease ≥20% and FEV1/FVC ＞0.70(28).
Taken together, there are different approaches in diag-
nosing rCLAD. A multimodal approach, using functional 
(i.e. lung function), radiologic and histopathologic evalua-
tion of the allograft is needed to diagnose rCLAD.
The prevalence of rCLAD is presumed about 30-35% 
based on several reports(6,25-27). And several reports 
showed that the survival rate after diagnosis of rCLAD was 
shorter than of BOS (0.8∼1.5 years vs. 3∼4 years)(6,25-27). 
However, further multicentric and prospective studies are 
needed to confirm the poor outcome of rCLAD compared 
to the patients with BOS.
There are some reports about risk factors for the develop-
ment of rCLAD. Those are severe lymphocytic bronchiolitis, 
late-onset diffuse alveolar damage, BAL eosinophilia, in-
creased BAL protein levels of alarmins, diagnosis of sarcoi-
dosis or interstitial lung diseases before transplantation, 
younger age, female gender, CMV donor/recipient mismatch 
and other risk factors which are common in BOS(29-32). 
However, those risk factors were derived from small studies 
and were not applied to other groups with rCLAD. There-
fore, the significance of reported risk factors for develop-
ment of rCLAD is still speculative.
The treatment of rCLAD remains unknown. The same 
therapeutic options for BOS are usually been tried, however, 
the most options showed the fail. There are some reports 
about possible improvement with pirfenidone, an antifibrotic 
agent, recently used for the treatment of IPF, or alemtuzu-
mab (Campatho-1H), an antagonist of CD52, which showed 
the interstitial changes and lung function in small group 
with rCLAD (33,34). Several centers reported that patients 
with rCLAD were likely to have DSA more frequently(35), 
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which may be the key of new treatment options. Further 
larger and multi-center study will be necessary to find a 
possible management. And unfortunately, the results of 
re-transplantation in patients with rCLAD are much worse 
than with BOS, therefore, strict selection criteria for 
re-transplantation for rCLAD should be applied(36).
Conclusion
In summary, CLAD was recently suggested concept in-
cluding different phenotypes of BOS and rCLAD (RAS). 
Different pathophysiological mechanisms may be involved 
these distinct phenotypes, because histology, allograft func-
tion and imaging are different. However, at present, we 
don’t know about definite pathophysiology, risk factors and 
treatment. Future research on pathophysiology, mechanisms 
and natural history is needed, only by doing we can under-
stand the basis for development of therapeutic options. This 
is the hope for LTx patients to live long overcoming CLAD.
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